Last reviewed · How we verify
IV Sodium Chloride 0.9 % — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
IV Sodium Chloride 0.9 % (IV Sodium Chloride 0.9 %) — Pr. Nicolas GIRERD.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| IV Sodium Chloride 0.9 % TARGET | IV Sodium Chloride 0.9 % | Pr. Nicolas GIRERD | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- IV Sodium Chloride 0.9 % CI watch — RSS
- IV Sodium Chloride 0.9 % CI watch — Atom
- IV Sodium Chloride 0.9 % CI watch — JSON
- IV Sodium Chloride 0.9 % alone — RSS
Cite this brief
Drug Landscape (2026). IV Sodium Chloride 0.9 % — Competitive Intelligence Brief. https://druglandscape.com/ci/iv-sodium-chloride-0-9. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab